Blocking myostatin protects bone from breast cancer damage in mice

Bone is the most common site of breast cancer metastasis. Tumor cells and bone-resorbing osteoclasts sustain a destructive cycle: bone breakdown releases factors such as TGF-β and calcium, which further stimulate tumor growth. Myostatin, a TGF-β family member best known for limiting muscle growth, was already known to promote osteoclast formation in arthritis models. This study investigated its role in breast cancer-associated bone destruction.

The researchers examined bone metastases from 27 breast cancer patients. All biopsies were myostatin-positive; the source reports 17 with moderate-to-high expression and 10 with low expression. It reports moderate-to-high staining most frequently in luminal B tumors, followed by luminal A and triple-negative tumors, although the subgroup percentages do not reconcile with the reported overall count. Myostatin-positive metastases were found at the osteoclast-rich bone–tumor interface. Circulating myostatin levels were comparable among patients with primary breast cancer alone, patients with primary cancer and bone metastases, and controls with non-invasive lesions. This supports, but does not prove, a local rather than systemic mechanism.

In vitro, 4T1 breast cancer cells increased osteoclast numbers 1.7-fold in direct co-culture and 2.9-fold through conditioned medium. An anti-myostatin antibody prevented these increases. In the 4T1 resorption assays, antibody treatment at 5 µg/ml reduced resorption-pit numbers by 70% in co-culture and 54% with conditioned medium, and reduced resorbed area by 42% in both settings. The supplied results also establish myostatin expression in MDA-MB-231 cells and their bone metastases, but end before detailed functional results for this cell line. The abstract reports that antibody blockade attenuated osteoclast formation and resorptive activity by inhibiting SMAD2 phosphorylation.

The mouse models used intracardiac injection of murine 4T1 cells and caudal-artery injection of human MDA-MB-231 cells into immunodeficient NSG mice. According to the abstract, targeting myostatin in both models increased bone density and muscle mass and reduced osteoclast numbers compared with controls. Treatment also decreased bone metastatic burden in MDA-MB-231-bearing mice. The supplied excerpt does not provide detailed in vivo treatment schedules, effect sizes or a treatment comparison for 4T1 tumor burden.

Together, these findings identify myostatin as a potential target for breast cancer-associated bone destruction, with possible muscle benefits. The human evidence is descriptive, while treatment efficacy was assessed in laboratory and mouse experiments. Clinical benefit, safety, dosing and compatibility with established bone-targeting therapies remain unestablished by the supplied evidence.